          From Wikipedia, the free encyclopedia                            Jump to:     navigation,      search           Emibetuzumab  Monoclonal antibody   Type ?   Source Humanized (from mouse)   Target HGFR   Identifiers   CAS Number 1365287-97-3   ATC code none   IUPHAR/BPS 7748   ChemSpider none   Chemical data   Formula C6356H9810N1694O2014S48   Molar mass 143.7 kg/mol   Emibetuzumab[1] is a monoclonal antibody designed for the treatment of cancer.[2] This drug was developed by Eli Lilly & Company. References[edit]  ^ World Health Organization (2014). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 111" (PDF). WHO Drug Information 28 (2).  ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Emibetuzumab, American Medical Association.     This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it.   v t e              v t e   Monoclonal antibodies for tumors       Tumor ("-t(u[m])-")     Human ("-tumu-")    Adecatumumab Cixutumumab Conatumumab Daratumumab Drozitumab Duligotumab Dusigitumab Enfortumab vedotin Figitumumab Ganitumab Glembatumumab vedotin Intetumumab Iratumumab Lexatumumab Lucatumumab Mapatumumab Narnatumab Necitumumab Ofatumumab Olaratumab Panitumumab Patritumab Pritumumab Radretumab Rilotumumab Robatumumab Seribantumab Teprotumumab Tovetumab Vantictumab Votumumab Zalutumumab   "-melu-" (melanoma) Flanvotumab         Mouse ("-tumo-")    Altumomab pentetate Anatumomab mafenatox Arcitumomab Bectumomab Blinatumomab Detumomab Ibritumomab tiuxetan Minretumomab Mitumomab Moxetumomab pasudotox Naptumomab estafenatox Nofetumomab merpentan Pemtumomab† Pintumomab Racotumomab Satumomab pendetide Solitomab Taplitumomab paptox Tenatumomab Tositumomab 3F8   "-govo-" (ovarian tumor) Abagovomab Igovomab Oregovomab   "-pro-" (prostate tumor) Capromab pendetide   "-colo-" (colonic tumor) Edrecolomab Nacolomab tafenatox         Chimeric ("-tuxi-")    Amatuximab Bavituximab Brentuximab vedotin Cetuximab Derlotuximab biotin Dinutuximab Ensituximab Futuximab Girentuximab Indatuximab ravtansine Isatuximab Margetuximab Rituximab Siltuximab Ublituximab  "-mexi-" (melanoma): Ecromeximab        Humanized ("-tuzu-")    Alemtuzumab Bevacizumab Bivatuzumab mertansine Cantuzumab mertansine Cantuzumab ravtansine Citatuzumab bogatox Clivatuzumab tetraxetan Dacetuzumab Dalotuzumab Elotuzumab† Emibetuzumab Enoblituzumab Etaracizumab Farletuzumab Ficlatuzumab Gemtuzumab ozogamicin Imgatuzumab Inotuzumab ozogamicin Labetuzumab Lifastuzumab vedotin Lintuzumab Lorvotuzumab mertansine Matuzumab§ Milatuzumab Nimotuzumab Obinutuzumab Ocaratuzumab Otlertuzumab Onartuzumab Oportuzumab monatox Parsatuzumab Pertuzumab Pinatuzumab vedotin Polatuzumab vedotin Sibrotuzumab Simtuzumab Tacatuzumab tetraxetan Tigatuzumab Trastuzumab Tucotuzumab celmoleukin Veltuzumab Vorsetuzumab mafodotin   "-gozu-" (ovarian tumor) Sofituzumab vedotin         Rat/mouse hybrid ("-tumaxo-")    Catumaxomab Ertumaxomab         Chimeric + humanized ("-tuxizu-")    Ontuxizumab                #WHO-EM ‡Withdrawn from market Clinical trials:  †Phase III §Never to phase III                    v t e   Growth factor receptor modulators       Angiopoietin    Agonists: Angiopoietin 1 Angiopoietin 4   Antagonists: Angiopoietin 2 Angiopoietin 3   Antibodies: Evinacumab (against angiopoietin 3) Nesvacumab (against angiopoietin 2)         CNTF    Agonists: Axokine CNTF Dapiclermin         EGF (ErbB)      EGF (ErbB1/HER1)     Agonists: Amphiregulin Betacellulin EGF (urogastrone) Epigen Epiregulin Heparin-binding EGF-like growth factor (HB-EGF) Murodermin Nepidermin Transforming growth factor alpha (TGFα)   Antibodies: Cetuximab Futuximab Imgatuzumab Matuzumab Necitumumab Nimotuzumab Panitumumab Zalutumumab   Kinase inhibitors: Afatinib AG-490 Brigatinib Canertinib Dacomitinib Erlotinib Gefitinib Grandinin Icotinib Lapatinib Neratinib Osimertinib Vandetanib WHI-P 154          ErbB2/HER2     Agonists: Unknown/none   Antibodies: Ertumaxomab Pertuzumab Trastuzumab Trastuzumab emtansine   Kinase inhibitors: Afatinib AG-490 Lapatinib Mubritinib Neratinib          ErbB3/HER3     Agonists: Neuregulins (heregulins) (1, 2, 6 (neuroglycan C))   Antibodies: Duligotumab Patritumab Seribantumab          ErbB4/HER4     Agonists: Betacellulin Epigen Heparin-binding EGF-like growth factor (HB-EGF) Neuregulins (heregulins) (1, 2, 3, 4, 5 (tomoregulin, TMEFF))            FGF      FGFR1     Ersofermin FGF (1, 2 (bFGF), 3, 4, 5, 6, 8, 10 (KGF2), 20) Repifermin Trafermin Velafermin          FGFR2     Ersofermin FGF (1, 2 (bFGF), 3, 4, 5, 6, 7 (KGF), 8, 9, 10 (KGF2), 17, 18, 22) Palifermin Repifermin Sprifermin Trafermin          FGFR3     Ersofermin FGF (1, 2 (bFGF), 4, 8, 9, 18, 23) Sprifermin Trafermin          FGFR4     Ersofermin FGF (1, 2 (bFGF), 4, 6, 8, 9, 19) Trafermin          Unsorted     FGF15/19            HGF (c-Met)    Agonists: Hepatocyte growth factor   Potentiators: Dihexa (PNB-0408)   Antibodies: Emibetuzumab Ficlatuzumab Flanvotumab Onartuzumab Rilotumumab   Kinase inhibitors: AM7 (drug) AMG-458 Amuvatinib BMS-777607 Cabozantinib Crizotinib Foretinib Golvatinib INCB28060 JNJ-38877605 K252a MK-2461 PF-04217903 PF-2341066 PHA-665752 SU-11274 Tivantinib Volitinib         IGF      IGF-1     Agonists: des(1-3)IGF-1 Insulin-like growth factor-1 (somatomedin C) IGF-1 LR3 Insulin-like growth factor-2 (somatomedin A) Insulin Mecasermin Mecasermin rinfabate   Antagonists: BMS-754807   Antibodies: AVE1642 Cixutumumab Dalotuzumab Figitumumab Ganitumab Robatumumab R1507 Teprotumumab   Kinase inhibitors: Linsitinib NVP-ADW742 NVP-AEW541 OSl-906          IGF-2     Agonists: Insulin-like growth factor-2 (somatomedin A)   Antibodies: Dusigitumab          Others     Binding proteins: IGFBP (1, 2, 3, 4, 5, 6, 7)   Cleavage products/derivatives with unknown target: Glypromate (GPE, (1-3)IGF-1) Trofinetide            LNGF    Agonists: BDNF NGF NT-3 NT-4   Antagonists: SAR127963   Antibodies: Against NGF: Fasinumab Fulranumab Tanezumab         PDGF    Agonists: Becaplermin Platelet-derived growth factor (A, B, C, D)   Antibodies: Olaratumab Ramucirumab Tovetumab   Kinase inhibitors: Axitinib Crenolanib Imatinib Lenvatinib Masitinib Motesanib Nintedanib Pazopanib Radotinib Quizartinib Sunitinib Sorafenib Toceranib         RET (GFL)      GFRα1     Agonists: Glial cell line-derived neurotrophic factor (GDNF) Liatermin   Kinase inhibitors: Vandetanib          GFRα2     Agonists: Neurturin (NRTN)   Kinase inhibitors: Vandetanib          GFRα3     Agonists: Artemin (ARTN)   Kinase inhibitors: Vandetanib          GFRα4     Agonists: Persephin (PSPN)   Kinase inhibitors: Vandetanib            SCF (c-Kit)    Agonists: Ancestim Stem cell factor   Kinase inhibitors: Axitinib Dasatinib Imatinib Masitinib Nilotinib Pazopanib Quizartinib Sorafenib Sunitinib Toceranib         TGFβ    See here instead.         Trk      TrkA     Agonists: Amitriptyline Gambogic amide NGF Tavilermide   Antagonists: FX007   Kinase inhibitors: Entrectinib K252a Lestaurtinib LOXO-101   Antibodies: Against NGF: Fasinumab Fulranumab Tanezumab          TrkB     Agonists: 3,7-DHF 3,7,8,2'-THF 4'-DMA-7,8-DHF 7,3'-DHF 7,8-DHF 7,8,2'-THF 7,8,3'-THF Amitriptyline BDNF Deoxygedunin Diosmetin HIOC LM22A-4 N-Acetylserotonin NT-3 NT-4 Norwogonin (5,7,8-THF) R7 TDP6   Antagonists: ANA-12 Cyclotraxin B Gossypetin (3,5,7,8,3',4'-HHF)   Kinase inhibitors: Entrectinib K252a Lestaurtinib LOXO-101          TrkC     Agonists: NT-3   Kinase inhibitors: Entrectinib K252a Lestaurtinib LOXO-101            VEGF    Agonists: Placental growth factor (PGF) Telbermin VEGF (A, B, C, D (FIGF))   Allosteric modulators: Cyclotraxin B   Antibodies: Alacizumab pegol Bevacizumab Icrucumab Ramucirumab Ranibizumab   Kinase inhibitors: Axitinib Cabozantinib Cediranib Lapatinib Lenvatinib Motesanib Nintedanib Pazopanib Pegaptanib Regorafenib Semaxanib Sorafenib Sunitinib Toceranib Tivozanib Vandetanib WHI-P 154   Decoy receptors: Aflibercept         Others    Additional growth factors: Adrenomedullin Colony-stimulating factors (see here instead) Connective tissue growth factor (CTGF) Ephrins (A1, A2, A3, A4, A5, B1, B2, B3) Erythropoietin (see here instead) Glucose-6-phosphate isomerase (GPI; PGI, PHI, AMF) Glia maturation factor (GMF) Hepatoma-derived growth factor (HDGF) Interleukins/T-cell growth factors (see here instead) Leukemia inhibitory factor (LIF) Macrophage-stimulating protein (MSP; HLP, HGFLP) Midkine (NEGF2) Migration-stimulating factor (MSF; PRG4) Oncomodulin Pituitary adenylate cyclase-activating peptide (PACAP) Pleiotrophin Renalase Thrombopoietin (see here instead) Wnt signaling proteins   Additional growth factor receptor modulators: Cerebrolysin (neurotrophin mixture)            See also: Peptide receptor modulators Cytokine receptor modulators                            Retrieved from "https://en.wikipedia.org/w/index.php?title=Emibetuzumab&oldid=722781675"          Categories: Drugs not assigned an ATC codeMonoclonal antibody stubsMonoclonal antibodiesHidden categories: Chemical articles having calculated molecular weight overwrittenDrugs that are a monoclonal antibodyArticles without EBI sourceChemicals that do not have a ChemSpider ID assignedChemical pages without DrugBank identifierArticles without KEGG sourceArticles without InChI sourceArticles without UNII sourceDrugs with no legal statusArticles containing unverified chemical infoboxesAll stub articles            
